NASDAQ · CTOR
Healthcare · Drug Manufacturers - General
$0.95
Up+$0.06 (+6.09%)
Updated Sep 17, 2026, 3:48 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CTOR closed at $0.95 after 20 trading sessions, up 26.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.89 | $0.9839 | $0.8533 | $0.9538 | 184.44K |
| Sep 15, 2026 | $0.95 | $0.9779 | $0.8502 | $0.856 | 118.27K |
| Sep 14, 2026 | $0.9201 | $0.9883 | $0.9145 | $0.94 | 69.27K |
| Sep 11, 2026 | $0.89 | $0.95 | $0.89 | $0.9175 | 138.26K |
| Sep 10, 2026 | $0.92 | $0.94 | $0.8684 | $0.91 | 49.44K |
| Sep 9, 2026 | $0.91 | $0.9599 | $0.8583 | $0.94 | 56.5K |
| Sep 8, 2026 | $0.913 | $0.94 | $0.8715 | $0.9291 | 220.81K |
| Sep 4, 2026 | $0.7666 | $0.8816 | $0.7501 | $0.86 | 54.79K |
| Sep 3, 2026 | $0.7999 | $0.80 | $0.7778 | $0.7922 | 13.95K |
| Sep 2, 2026 | $0.735 | $0.80 | $0.7252 | $0.7777 | 12.12K |
| Sep 1, 2026 | $0.7701 | $0.7771 | $0.7245 | $0.75 | 16.59K |
| Aug 31, 2026 | $0.82 | $0.82 | $0.7529 | $0.7632 | 38.71K |
| Aug 28, 2026 | $0.80 | $0.80 | $0.7538 | $0.7756 | 21.7K |
| Aug 27, 2026 | $0.8275 | $0.83 | $0.7903 | $0.7903 | 8.57K |
| Aug 26, 2026 | $0.7908 | $0.82 | $0.7516 | $0.7871 | 17.08K |
| Aug 25, 2026 | $0.705 | $0.818 | $0.705 | $0.8101 | 134.13K |
| Aug 24, 2026 | $0.759 | $0.76 | $0.7222 | $0.75 | 16.69K |
| Aug 21, 2026 | $0.721 | $0.7549 | $0.721 | $0.7438 | 13.46K |
| Aug 20, 2026 | $0.7524 | $0.7734 | $0.71 | $0.7591 | 52.09K |
| Aug 19, 2026 | $0.73 | $0.78 | $0.6801 | $0.7525 | 58.03K |
The latest Smart Investors Daily articles mentioning CTOR.
CTOR research
Company profile and research snapshot.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Buy | — |
| May 23, 2025 | Maxim Group | Hold | — |
| Nov 27, 2024 | Maxim Group | Buy | — |
| Aug 13, 2024 | EF Hutton | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.
Benzinga · Aug 14, 2026
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Yahoo · Aug 12, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.
Yahoo · Aug 5, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTOR.
